EWTX250117C35000
- 0.10
- 0.000.00%
Edgewise Therapeutics Newsroom
Stifel Maintains Edgewise Therapeutics(EWTX.US) With Hold Rating, Maintains Target Price $30
Edgewise Therapeutics Analyst Ratings
Stifel Initiates Edgewise Therapeutics(EWTX.US) With Hold Rating, Announces Target Price $30
Edgewise Therapeutics: Strategic Positioning and Promising Clinical Advancements Support Buy Rating
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $51
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
Truist Financial Remains a Buy on Edgewise Therapeutics (EWTX)
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Edgewise Therapeutics (EWTX) and Avadel Pharmaceuticals (AVDL)
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $50
Edgewise Therapeutics Analyst Ratings
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50
A Quick Look at Today's Ratings for Edgewise Therapeutics(EWTX.US), With a Forecast Between $50 to $50
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $44
Edgewise Therapeutics Analyst Ratings
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
Edgewise Therapeutics Initiated at Outperform by Evercore ISI Group
Evercore Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $45
Edgewise Therapeutics Is Maintained at Outperform by Wedbush